CN104086650B - 人7型腺病毒的中和性单克隆抗体及其制备方法和应用 - Google Patents
人7型腺病毒的中和性单克隆抗体及其制备方法和应用 Download PDFInfo
- Publication number
- CN104086650B CN104086650B CN201410267112.3A CN201410267112A CN104086650B CN 104086650 B CN104086650 B CN 104086650B CN 201410267112 A CN201410267112 A CN 201410267112A CN 104086650 B CN104086650 B CN 104086650B
- Authority
- CN
- China
- Prior art keywords
- monoclonal antibody
- type adenovirus
- people
- adenovirus
- neutralizing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000701161 unidentified adenovirus Species 0.000 title claims abstract description 81
- 230000003472 neutralizing effect Effects 0.000 title claims abstract description 25
- 238000002360 preparation method Methods 0.000 title description 6
- 210000004408 hybridoma Anatomy 0.000 claims abstract description 14
- 230000003248 secreting effect Effects 0.000 claims description 2
- 241000700605 Viruses Species 0.000 abstract description 37
- 238000000034 method Methods 0.000 abstract description 34
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 abstract description 22
- 230000002163 immunogen Effects 0.000 abstract description 13
- 239000013598 vector Substances 0.000 abstract description 11
- 230000000694 effects Effects 0.000 abstract description 10
- 208000035473 Communicable disease Diseases 0.000 abstract description 4
- 208000015181 infectious disease Diseases 0.000 abstract description 4
- 229940126622 therapeutic monoclonal antibody Drugs 0.000 abstract description 4
- 230000028993 immune response Effects 0.000 abstract description 3
- 239000004615 ingredient Substances 0.000 abstract description 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 2
- 238000002474 experimental method Methods 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 20
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 108090000765 processed proteins & peptides Proteins 0.000 description 13
- 238000010790 dilution Methods 0.000 description 11
- 239000012895 dilution Substances 0.000 description 11
- 230000036039 immunity Effects 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 210000002845 virion Anatomy 0.000 description 11
- 239000013612 plasmid Substances 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 206010003445 Ascites Diseases 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- 239000003085 diluting agent Substances 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- 125000003275 alpha amino acid group Chemical group 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 238000012216 screening Methods 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 5
- 210000004907 gland Anatomy 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000031700 light absorption Effects 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 238000006386 neutralization reaction Methods 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 231100000614 poison Toxicity 0.000 description 4
- 239000002574 poison Substances 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 101000666856 Homo sapiens Vasoactive intestinal polypeptide receptor 1 Proteins 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- 238000012408 PCR amplification Methods 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 102100038388 Vasoactive intestinal polypeptide receptor 1 Human genes 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 230000006801 homologous recombination Effects 0.000 description 3
- 238000002744 homologous recombination Methods 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 235000011149 sulphuric acid Nutrition 0.000 description 3
- 239000001117 sulphuric acid Substances 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 239000013603 viral vector Substances 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 238000011725 BALB/c mouse Methods 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 2
- 206010057190 Respiratory tract infections Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 229910052792 caesium Inorganic materials 0.000 description 2
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 238000000799 fluorescence microscopy Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229940005654 nitrite ion Drugs 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000013605 shuttle vector Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 208000010370 Adenoviridae Infections Diseases 0.000 description 1
- 206010060931 Adenovirus infection Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 208000011589 adenoviridae infectious disease Diseases 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000005090 green fluorescent protein Substances 0.000 description 1
- 230000006054 immunological memory Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000004531 microgranule Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- -1 nitrite ions Chemical class 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Landscapes
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410267112.3A CN104086650B (zh) | 2014-06-16 | 2014-06-16 | 人7型腺病毒的中和性单克隆抗体及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410267112.3A CN104086650B (zh) | 2014-06-16 | 2014-06-16 | 人7型腺病毒的中和性单克隆抗体及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104086650A CN104086650A (zh) | 2014-10-08 |
CN104086650B true CN104086650B (zh) | 2017-01-04 |
Family
ID=51634433
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410267112.3A Active CN104086650B (zh) | 2014-06-16 | 2014-06-16 | 人7型腺病毒的中和性单克隆抗体及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104086650B (zh) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109295002B (zh) * | 2018-07-13 | 2021-11-19 | 广州医科大学附属第一医院 | 杂交瘤细胞、单克隆抗体及其制备方法和应用 |
CN109957009B (zh) * | 2019-03-28 | 2021-03-19 | 中国人民解放军军事科学院军事医学研究院 | 抗人7型腺病毒抗体2-1h及其应用 |
CN109897104B (zh) * | 2019-03-28 | 2020-12-22 | 中国人民解放军军事科学院军事医学研究院 | 人7型腺病毒单克隆抗体3-3e及其应用 |
CN110294802B (zh) * | 2019-07-08 | 2020-07-14 | 中国人民解放军军事科学院军事医学研究院 | 一种单克隆抗体10g12及其应用 |
JP7256144B2 (ja) * | 2020-04-16 | 2023-04-11 | デンカ株式会社 | アデノウイルスの免疫測定方法及び免疫測定器具 |
CN113651882B (zh) * | 2021-08-04 | 2022-06-10 | 广州呼研所医药科技有限公司 | 人源化抗HAdV-B3单克隆中和抗体、制备方法及其应用 |
CN113651883B (zh) * | 2021-08-04 | 2022-06-10 | 广州呼研所医药科技有限公司 | 人源化抗HAdV-B7单克隆中和抗体、制备方法及其应用 |
CN116789807B (zh) * | 2023-06-14 | 2024-01-16 | 珠海重链生物科技有限公司 | 抗腺病毒单克隆抗体及其应用 |
-
2014
- 2014-06-16 CN CN201410267112.3A patent/CN104086650B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN104086650A (zh) | 2014-10-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104086650B (zh) | 人7型腺病毒的中和性单克隆抗体及其制备方法和应用 | |
Alharbi et al. | ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice | |
Gall et al. | Construction and characterization of hexon-chimeric adenoviruses: specification of adenovirus serotype | |
Bárcena et al. | Horizontal transmissible protection against myxomatosis and rabbit hemorrhagic disease by using a recombinant myxoma virus | |
Wang et al. | Receptor-binding domain of MERS-CoV with optimal immunogen dosage and immunization interval protects human transgenic mice from MERS-CoV infection | |
Okba et al. | Particulate multivalent presentation of the receptor binding domain induces protective immune responses against MERS-CoV | |
Nunes et al. | A synthetic biology approach for a vaccine platform against known and newly emerging serotypes of bluetongue virus | |
US10172932B2 (en) | Ebola virus disease vaccine taking human replication deficient adenovirus as vector | |
Alharbi | Vaccines against Middle East respiratory syndrome coronavirus for humans and camels | |
CN111088271A (zh) | 一种基于复制缺陷型重组腺病毒载体的寨卡病毒疫苗 | |
Excler et al. | Toward developing a preventive MERS-CoV vaccine—report from a workshop organized by the Saudi Arabia Ministry of Health and the International Vaccine Institute, Riyadh, Saudi Arabia, November 14–15, 2015 | |
Liu et al. | Evaluation of the efficacy of a recombinant adenovirus expressing the spike protein of porcine epidemic diarrhea virus in pigs | |
Lardinois et al. | Stronger interference of avian influenza virus–specific than Newcastle disease virus–specific maternally derived antibodies with a recombinant NDV-H5 vaccine | |
CN105274142B (zh) | 复制型重组人55型腺病毒载体及其制备方法和应用 | |
Mu et al. | A novel Fiber-1-edited and highly attenuated recombinant serotype 4 fowl adenovirus confers efficient protection against lethal challenge | |
Verardi et al. | Long-term sterilizing immunity to rinderpest in cattle vaccinated with a recombinant vaccinia virus expressing high levels of the fusion and hemagglutinin glycoproteins | |
Douglass et al. | The development of dual vaccines against lumpy skin disease (LSD) and bovine ephemeral fever (BEF) | |
Mitchell et al. | Epitope mapping of Ebola virus dominant and subdominant glycoprotein epitopes facilitates construction of an epitope-based DNA vaccine able to focus the antibody response in mice | |
Myers et al. | Impact of adjuvant: Trivalent vaccine with quadrivalent-like protection against heterologous Yamagata-lineage influenza B virus | |
CN115698058A (zh) | 抗SARS-CoV-2刺突蛋白单克隆抗体 | |
Li et al. | Comprehensive analysis and characterization of linear antigenic domains on HN protein from genotype VII Newcastle disease virus using yeast surface display system | |
CN105504051B (zh) | 狂犬病毒核蛋白单克隆抗体及其应用 | |
Onodera et al. | Immune-focusing properties of virus-like particles improve protective IgA responses | |
Hao et al. | An adenovirus-vectored RVF vaccine confers complete protection against lethal RVFV challenge in A129 mice | |
CN107557347A (zh) | 肠道病毒71型的新型病毒样颗粒、其制备方法及应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20180917 Address after: 510630 room 505, building A, 1 Rui FA Road, Luogang District, Guangzhou, Guangdong. Patentee after: Guangzhou rufa No.1 Investment Management Center (general partnership) Address before: 510663 Room A1211, Guangzhou International Business Incubator Area A, No. 3 Yuquan Road, Scientific City, Guangzhou High-tech Industrial Development Zone, Guangdong Province Patentee before: GUANGZHOU RIDA BIOTECH Co.,Ltd. |
|
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: Room 505, Building A, No.1 Ruifa Road, Luogang District, Guangzhou City, Guangdong Province, 510000 Patentee after: Guangzhou Ruifa No.1 Health Investment Center (L.P.) Country or region after: China Address before: 510630 room 505, building A, 1 Rui FA Road, Luogang District, Guangzhou, Guangdong. Patentee before: Guangzhou rufa No.1 Investment Management Center (general partnership) Country or region before: China |